Regeneron and Sanofi Present Positive Phase 3 Results for Dupixent in Chronic Spontaneous Urticaria

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi will present positive data from the Phase 3 LIBERTY-CUPID Study C evaluating the inves...

October 25, 2024 | Friday | News
Biogen to Present Key Findings at Clinical Trials on Alzheimer’s Disease Conference

Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the Clinical Trials on Alzheimer’s Disease (CTAD) annual con...

October 25, 2024 | Friday | News
AbbVie and Gedeon Richter Forge New Agreement to Explore Treatments for Neuropsychiatric Disorders

 AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') announced a new discovery, co-development and license agreement to advance novel targets for ...

October 25, 2024 | Friday | News
GSK Announces Promising Data for Arexvy Vaccine in Younger Adults at Risk for RSV

GSK plc (LSE/NYSE: GSK) announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at inc...

October 25, 2024 | Friday | News
Biogen to Showcase Promising Data on Felzartamab at Kidney Week 2024

Biogen Inc. (Nasdaq: BIIB) – announced the company will present a variety of new data from its felzartamab clinical development program at Kidne...

October 23, 2024 | Wednesday | News
Sanofi and CD&R Announce Exclusive Negotiations for 50% Stake in Opella, Poised to Create Global Consumer Healthcare Leader

 Sanofi and CD&R announce a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion. S...

October 22, 2024 | Tuesday | News
Catalent CEO John Chiminski Issues Open Letter Addressing Novo Holdings’ Acquisition and Reaffirms Commitment to Customers

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, issued the following open lette...

October 22, 2024 | Tuesday | News
Foresee Pharmaceuticals Completes Phase 1 Trial of Linvemastat, a Promising Oral MMP-12 Inhibitor for Respiratory and IBD Conditions

Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announced the successful completion of its Phase 1 single and multiple ascending dose (SAD/MAD) clinical ...

October 21, 2024 | Monday | News
BOTOX® Cosmetic Gains FDA Approval for Treatment of Platysma Bands, Expanding Aesthetic Options Beyond the Face

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of BOTOX® Cosmetic for temporary improvement in the appearanc...

October 21, 2024 | Monday | News
MSD and Gilead Announce Promising Results for Once-Weekly HIV Treatment in Phase 2 Study

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced new results from a Phase 2 clin...

October 21, 2024 | Monday | News
Antengene Secures South Korean Approval for XPOVIO® in Combination Therapy for Multiple Myeloma

SHANGHAI and HONG KONG, Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmac...

October 18, 2024 | Friday | News
AbbVie Receives FDA Approval for VYALEV™: First Continuous Subcutaneous Infusion Therapy for Advanced Parkinson's Disease

AbbVie (NYSE: ABBV) announced that the U.S. Food and Drug Administration (FDA) has approved VYALEV™ (foscarbidopa and foslevodopa) as the first and o...

October 18, 2024 | Friday | News
MSD's Clesrovimab Shows Promising Results in Protecting Infants from RSV in Phase 2b/3 Trial

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the presentation of positive results from the Phase 2b/3 clinical trial ...

October 18, 2024 | Friday | News
Innovent Biologics Announces Successful Phase 2 Results for Picankibart in Treating Ulcerative Colitis

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

October 17, 2024 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close